INTERVIEWS

Dr. Todd Chappell, board-certified OB/GYN discusses a new study in the “Journal of Sexual Medicine” that found that women using the non-hormonal birth control method Phexxi ®, an on-demand prescription contraceptive gel, reported improvement in or the maintenance of their sexual satisfaction.

Navya Davuluri, Co-Founder and Chief Executive Officer of Curie AI, a virtual respiratory care provider, discusses how they are leveraging AI to capture sleep noises and patterns to proactively get ahead of COPD and other respiratory issues.   She talks about why management of COPD has been difficult for patients, why people in urban environments tend to have more respiratory issues than in suburban, how living in a rural area affects treatment options and access to care, and why healthcare is slow to adopt AI.   

Dr. Jessica Shepherd, OB/GYN, and Organon Health Partner discusses the importance of cultural sensitivity in the doctor’s office and how healthcare providers can help close disparity gaps, particularly in women’s health. She addresses the ways stigma can impact health outcomes, how access, education, and patient goals may differ based on background and culture, conditions unique to women that disproportionately impact women of color, and steps providers can take to facilitate open conversation and help reduce medical bias. Listeners can visit a new resource from Organon, a global women’s health company, to learn more about what the company is also doing to put the spotlight on women’s health. 

Dr. Alok Patel, a pediatric hospitalist, discusses the benefits of clean-label, whole plant-based nutrition for babies and toddlers. He talks about why industrial and environmental contaminants, along with toxins in food and consumer products, are so dangerous and why adding this important information to food labels is essential. Parents should pay particular attention to ingredients in infant cereals, often the first food consumed by babies after breastmilk and formula. 

Returning guest, Dr. Jan Wehkamp, M.D., Ph.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC discusses new data on TREMFYA ® (guselkumab) in ulcerative colitis (UC) and Crohn’s disease (CD) and new data on STELARA ® (ustekinumab) in UC and CD that was presented at the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2022.

Emily Goetz, VP of Commercial at Bright.md, an asynchronous virtual care platform, discusses misconceptions around asynchronous telehealth and elaborates on how asynchronous care options can help address some of the major challenges healthcare organizations currently face, like workforce shortages, consumerization of care, patient access, and more. 

Kathy Sapp, CEO of The American Chronic Pain Association, a philanthropic organization, and Dr. David Armstrong, podiatric surgeon, and researcher with Keck School of Medicine at the University of Southern California discuss nerve damage caused by diabetes called diabetic peripheral neuropathy (DPN) or diabetic nerve pain as it is most commonly called.   They also talk about an educational campaign called “Name That Pain” launched by Averitas Pharma,  the American Chronic Pain Association, and members of the medical and patient community to raise awareness and emphasize the importance of identifying symptoms of diabetic nerve pain and talking with a healthcare provider early in the treatment journey.   

Dr. Rakesh Jain, Clinical Professor, Department of Psychiatry, Texas Tech School of Medicine, Austin, TX discusses tardive dyskinesia or TD, a chronic condition characterized by uncontrollable body movements that can occur in one or more areas of the body. TD is associated with taking certain mental health medications. 

Miki Rossanis, Head of Clinical Development at Sensi.AI, based in Tel Aviv, discusses the world’s first AI-powered in-home virtual care agent. Sensi’s technology takes on the growing challenges in long term care by providing data that helps in extending the limited human workforce that takes care of our older adults. Rather than aiming to replace human, high touch care, Sensi enables care providers to optimize their service, and provides a layer of support when there is no in-home human care present. Sensi’s technology provides predictive analytics of behaviors as well as cognitive and physical changes, identifying risk factors before they materialize and cause irreversible damage. Sensi is an invaluable tool in mitigating risk, aiding in early detection of conditions, and understanding and supporting the home environment and its myriad challenges for care. 

Returning guest, Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC discusses new data showing TREMFYA ® (guselkumab) provides safe and durable skin clearance through five years in moderate to severe plaque psoriasis (PsO), regardless of baseline disease characteristics or metabolic comorbidities, and meaningful clinical improvements in sexual dysfunction, social relationship dysfunction, and fatigue. These data were presented at the Academy of Dermatology (AAD) annual meeting 2022.